531 related articles for article (PubMed ID: 10836293)
61. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
[TBL] [Abstract][Full Text] [Related]
62. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
[TBL] [Abstract][Full Text] [Related]
63. Low-grade serous tumors of ovary.
Bell DA
Int J Gynecol Pathol; 2014 Jul; 33(4):348-56. PubMed ID: 24901394
[TBL] [Abstract][Full Text] [Related]
64. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
65. Serous and mucinous borderline (low malignant potential) tumors of the ovary.
Acs G
Am J Clin Pathol; 2005 Jun; 123 Suppl():S13-57. PubMed ID: 16100867
[TBL] [Abstract][Full Text] [Related]
66. [Ovarian serous tumors of limited malignancy and invasive peritoneal implants. Review of the literature].
Fondrinier E; Seince N; Verriele V; Lorimier G; Gamelin E
Contracept Fertil Sex; 1999 Nov; 27(11):780-4. PubMed ID: 10609410
[TBL] [Abstract][Full Text] [Related]
67. Management of borderline ovarian tumors.
Tîrnovanu MC; Amancei S; Dumitrescu A; Onofriescu M; Dumitraşcu I
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1069-75. PubMed ID: 23700890
[TBL] [Abstract][Full Text] [Related]
68. Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary in 18 Patients With Peritoneal Carcinomatosis.
Seidman JD; Savage J; Krishnan J; Vang R; Kurman RJ
Int J Gynecol Pathol; 2020 Jan; 39(1):43-54. PubMed ID: 30480646
[TBL] [Abstract][Full Text] [Related]
69. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
70. A comparative analysis of lymphatic vessel density in ovarian serous tumors of low malignant potential (borderline tumors) with and without lymph node involvement.
Fadare O; Orejudos MP; Jain R; Mariappan MR; Hecht JL; Renshaw IL; Hileeto D; Wang SA; Ghofrani M; Liang SX
Int J Gynecol Pathol; 2008 Oct; 27(4):483-90. PubMed ID: 18753975
[TBL] [Abstract][Full Text] [Related]
71. [Pitfalls and common problems in the differential diagnosis of epithelial ovarian tumors].
Lax SF
Pathologe; 2019 Feb; 40(1):46-60. PubMed ID: 30719693
[TBL] [Abstract][Full Text] [Related]
72. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
73. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors.
Burks RT; Sherman ME; Kurman RJ
Am J Surg Pathol; 1996 Nov; 20(11):1319-30. PubMed ID: 8898836
[TBL] [Abstract][Full Text] [Related]
74. Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome.
Avril S; Hahn E; Specht K; Hauptmann S; Höss C; Kiechle M; Höfler H; Schmalfeldt B
Gynecol Oncol; 2012 Dec; 127(3):516-24. PubMed ID: 23000388
[TBL] [Abstract][Full Text] [Related]
75. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence.
Morice P; Uzan C; Fauvet R; Gouy S; Duvillard P; Darai E
Lancet Oncol; 2012 Mar; 13(3):e103-15. PubMed ID: 22381933
[TBL] [Abstract][Full Text] [Related]
76. Metastatic serous borderline ovarian tumor in an internal mammary lymph node: a case report and review of the literature.
Chamberlin MD; Eltabbakh GH; Mount SL; Leavitt BJ
Gynecol Oncol; 2001 Jul; 82(1):212-5. PubMed ID: 11426990
[TBL] [Abstract][Full Text] [Related]
77. Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors.
Vancraeynest E; Moerman P; Leunen K; Amant F; Neven P; Vergote I
Int J Gynecol Cancer; 2016 Oct; 26(8):1399-406. PubMed ID: 27465897
[TBL] [Abstract][Full Text] [Related]
78. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
79. Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor).
Kadar N; Krumerman M
Gynecol Oncol; 1995 Dec; 59(3):394-7. PubMed ID: 8522262
[TBL] [Abstract][Full Text] [Related]
80. Calretinin, CD34, and alpha-smooth muscle actin in the identification of peritoneal invasive implants of serous borderline tumors of the ovary.
Lee ES; Leong AS; Kim YS; Lee JH; Kim I; Ahn GH; Kim HS; Chun YK
Mod Pathol; 2006 Mar; 19(3):364-72. PubMed ID: 16415795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
